MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
InspireMD Cost of Revenue 2011-2026 | NSPR
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue InspireMD
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.33 M | 5.5 M | 4.4 M | 4.05 M | 3.74 M | 2.4 M | 2.96 M | 2.61 M | 2.18 M | 1.79 M | 2.61 M | 2.03 M | 2.28 M | 2.85 M | 3.01 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.33 M | 1.79 M | 3.25 M |
Quarterly Cost of Revenue InspireMD
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.66 M | 1.46 M | 1.24 M | - | 1.4 M | 1.41 M | 1.22 M | - | 1.12 M | 1.16 M | 866 K | - | 1.06 M | 1.1 M | 1.06 M | - | 979 K | 776 K | 900 K | - | 682 K | 433 K | 739 K | - | 811 K | 912 K | 488 K | - | 571 K | 726 K | 714 K | - | 565 K | 493 K | 495 K | - | 439 K | 478 K | 497 K | - | 543 K | 897 K | 514 K | - | 349 K | 584 K | 625 K | - | 750 K | 832 K | 750 K | 547 K | 230 K | 777 K | 230 K | 671 K | 801 K | 640 K | 899 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.66 M | 230 K | 789 K |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 12.93 | 1.02 % | $ 1.75 B |  USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.62 | -1.31 % | $ 38.6 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.22 | - | $ 121 M |  France |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 11.67 | -0.98 % | $ 330 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 95.25 | 0.39 % | $ 12.9 B | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
14 M | $ 26.39 | -0.34 % | $ 223 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.28 | 5.56 % | $ 1.39 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.41 | 1.36 % | $ 385 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 5.33 | -0.09 % | $ 1.13 B | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 63.87 | -0.51 % | $ 3.48 B |  Britain |
 |
LENSAR
LNSR
|
31.3 M | $ 5.08 | -0.2 % | $ 60.7 M | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.28 | 0.79 % | $ 52.1 M | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.97 | 1.2 % | $ 393 M | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.09 | 2.83 % | $ 18.5 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 39.18 | 2.08 % | $ 1.22 B | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 55.85 | -0.75 % | $ 1.64 B | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 191.14 | 0.83 % | $ 13.4 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 85.95 | -0.06 % | $ 2.99 B | USA |
 |
PAVmed
PAVM
|
218 K | $ 9.11 | 1.22 % | $ 6.11 M | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 83.94 | -0.37 % | $ 49.1 B | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 2.43 | -1.62 % | $ 6.74 M | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 3.46 | 0.87 % | $ 511 M | USA |
 |
Stryker Corporation
SYK
|
9.05 B | $ 328.6 | 0.34 % | $ 126 B | USA |
 |
Tactile Systems Technology
TCMD
|
79.4 M | $ 25.34 | 1.08 % | $ 580 M | USA |
 |
Nevro Corp.
NVRO
|
139 M | - | - | $ 217 M | USA |